-
Brean Initiates Relypsa With Buy Rating, $26 Target
Tuesday, March 29, 2016 - 9:32am | 291On Tuesday, Brean Capital issued a company note on Relypsa Inc (NASDAQ: RLYP), initiating coverage on the biopharmaceutical company after recent analysis of their drug Veltassa, which treats hyperkalemia. Currently, analysts at Brean Capital rate Relypsa as a Buy with a $26 price target. Difei...